VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
3882
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
698
Interactions with Platform & by Email
PARTICIPANTS
116
Unique # Participated
VALIDATIONS
52
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
111
PAGES
182
EDITION
8
PRICE
USD $4950
The U.S. Economy is Reinventing Itself to Weather Economic Storms.
Here's An Analytical Window into the Changing Opportunities.
Amid the COVID-19 crisis, the global market for Sickle Cell Disease Treatment estimated at US$397.7 Million in the year 2020, is projected to reach a revised size of US$589.5 Million by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Hydroxyurea, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$244.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antibiotics segment is readjusted to a revised 6.8% CAGR for the next 7-year period.
The Sickle Cell Disease Treatment market in the U.S. is estimated at US$117.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.5 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.
In the global Pain-Relieving Medications segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.8 Million in the year 2020 will reach a projected size of US$98.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$69.1 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 182-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Acceleron Pharma, Inc.; Alnylam Pharmaceuticals, Inc.; Arena Pharmaceuticals, Inc.; AstraZeneca PLC; Baxter International, Inc.; bluebird bio, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Emmaus Life Sciences, Inc.; Global Blood Therapeutics, Inc.; Novartis AG; Pfizer, Inc.; Sangamo Therapeutics, Inc.
» Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta Thalassemia, Other Disease Types) » Drug Type (Hydroxyurea, Antibiotics, Pain-Relieving Medications, Other Drug Types)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Sickle Cell Disease Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Sickle Cell Disease Treatment Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Sickle Cell Disease Treatment Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 |
| Sickle Cell Disease Treatment Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Sickle Cell Anemia (Disease Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Sickle Cell Anemia (Disease Type) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Sickle Cell Anemia (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Sickle Hemoglobin C Disease (Disease Type) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018 to 2025 |
| Sickle Hemoglobin C Disease (Disease Type) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Sickle Hemoglobin C Disease (Disease Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| Sickle Beta Thalassemia (Disease Type) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2018 to 2025 |
| Sickle Beta Thalassemia (Disease Type) Global Historic Demand in US$ Thousand by Region/Country: 2009 to 2017 |
| Sickle Beta Thalassemia (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Other Disease Types (Disease Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Other Disease Types (Disease Type) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Other Disease Types (Disease Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Hydroxyurea (Drug Type) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Hydroxyurea (Drug Type) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Hydroxyurea (Drug Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Antibiotics (Drug Type) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Antibiotics (Drug Type) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Antibiotics (Drug Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Pain-Relieving Medications (Drug Type) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025 |
| Pain-Relieving Medications (Drug Type) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017 |
| Pain-Relieving Medications (Drug Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Other Drug Types (Drug Type) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2018 to 2025 |
| Other Drug Types (Drug Type) Market Historic Review by Region/Country in US$ Thousand: 2009 to 2017 |
| Other Drug Types (Drug Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Sickle Cell Disease Treatment Market Share (in %) by Company: 2019 & 2025 |
| United States Sickle Cell Disease Treatment Market Estimates and Projections in US$ Thousand by Disease Type: 2018 to 2025 |
| Sickle Cell Disease Treatment Market in the United States by Disease Type: A Historic Review in US$ Thousand for 2009-2017 |
| United States Sickle Cell Disease Treatment Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| United States Sickle Cell Disease Treatment Market Estimates and Projections in US$ Thousand by Drug Type: 2018 to 2025 |
| Sickle Cell Disease Treatment Market in the United States by Drug Type: A Historic Review in US$ Thousand for 2009-2017 |
| United States Sickle Cell Disease Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| CANADA |
| Canadian Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Disease Type: 2018 to 2025 |
| Canadian Sickle Cell Disease Treatment Historic Market Review by Disease Type in US$ Thousand: 2009-2017 |
| Sickle Cell Disease Treatment Market in Canada: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025 |
| Canadian Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Drug Type: 2018 to 2025 |
| Canadian Sickle Cell Disease Treatment Historic Market Review by Drug Type in US$ Thousand: 2009-2017 |
| Sickle Cell Disease Treatment Market in Canada: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| JAPAN |
| Japanese Market for Sickle Cell Disease Treatment: Annual Sales Estimates and Projections in US$ Thousand by Disease Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Market in Japan: Historic Sales Analysis in US$ Thousand by Disease Type for the Period 2009-2017 |
| Japanese Sickle Cell Disease Treatment Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Japanese Market for Sickle Cell Disease Treatment: Annual Sales Estimates and Projections in US$ Thousand by Drug Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Market in Japan: Historic Sales Analysis in US$ Thousand by Drug Type for the Period 2009-2017 |
| Japanese Sickle Cell Disease Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| CHINA |
| Chinese Sickle Cell Disease Treatment Market Growth Prospects in US$ Thousand by Disease Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Historic Market Analysis in China in US$ Thousand by Disease Type: 2009-2017 |
| Chinese Sickle Cell Disease Treatment Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Chinese Sickle Cell Disease Treatment Market Growth Prospects in US$ Thousand by Drug Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Historic Market Analysis in China in US$ Thousand by Drug Type: 2009-2017 |
| Chinese Sickle Cell Disease Treatment Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| EUROPE |
| Market Facts & Figures |
| European Sickle Cell Disease Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Sickle Cell Disease Treatment Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| Sickle Cell Disease Treatment Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 |
| European Sickle Cell Disease Treatment Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Disease Type: 2018-2025 |
| Sickle Cell Disease Treatment Market in Europe in US$ Thousand by Disease Type: A Historic Review for the Period 2009-2017 |
| European Sickle Cell Disease Treatment Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| European Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Drug Type: 2018-2025 |
| Sickle Cell Disease Treatment Market in Europe in US$ Thousand by Drug Type: A Historic Review for the Period 2009-2017 |
| European Sickle Cell Disease Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| FRANCE |
| Sickle Cell Disease Treatment Market in France by Disease Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Sickle Cell Disease Treatment Historic Market Scenario in US$ Thousand by Disease Type: 2009-2017 |
| French Sickle Cell Disease Treatment Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Sickle Cell Disease Treatment Market in France by Drug Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Sickle Cell Disease Treatment Historic Market Scenario in US$ Thousand by Drug Type: 2009-2017 |
| French Sickle Cell Disease Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| GERMANY |
| Sickle Cell Disease Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Disease Type for the Period 2018-2025 |
| German Sickle Cell Disease Treatment Historic Market Analysis in US$ Thousand by Disease Type: 2009-2017 |
| German Sickle Cell Disease Treatment Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| Sickle Cell Disease Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Drug Type for the Period 2018-2025 |
| German Sickle Cell Disease Treatment Historic Market Analysis in US$ Thousand by Drug Type: 2009-2017 |
| German Sickle Cell Disease Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| ITALY |
| Italian Sickle Cell Disease Treatment Market Growth Prospects in US$ Thousand by Disease Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Historic Market Analysis in Italy in US$ Thousand by Disease Type: 2009-2017 |
| Italian Sickle Cell Disease Treatment Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Italian Sickle Cell Disease Treatment Market Growth Prospects in US$ Thousand by Drug Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Historic Market Analysis in Italy in US$ Thousand by Drug Type: 2009-2017 |
| Italian Sickle Cell Disease Treatment Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| UNITED KINGDOM |
| United Kingdom Market for Sickle Cell Disease Treatment: Annual Sales Estimates and Projections in US$ Thousand by Disease Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Disease Type for the Period 2009-2017 |
| United Kingdom Sickle Cell Disease Treatment Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| United Kingdom Market for Sickle Cell Disease Treatment: Annual Sales Estimates and Projections in US$ Thousand by Drug Type for the Period 2018-2025 |
| Sickle Cell Disease Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Drug Type for the Period 2009-2017 |
| United Kingdom Sickle Cell Disease Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| REST OF EUROPE |
| Rest of Europe Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Disease Type: 2018-2025 |
| Sickle Cell Disease Treatment Market in Rest of Europe in US$ Thousand by Disease Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Sickle Cell Disease Treatment Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025 |
| Rest of Europe Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Drug Type: 2018-2025 |
| Sickle Cell Disease Treatment Market in Rest of Europe in US$ Thousand by Drug Type: A Historic Review for the Period 2009-2017 |
| Rest of Europe Sickle Cell Disease Treatment Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025 |
| ASIA-PACIFIC |
| Sickle Cell Disease Treatment Market in Asia-Pacific by Disease Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Sickle Cell Disease Treatment Historic Market Scenario in US$ Thousand by Disease Type: 2009-2017 |
| Asia-Pacific Sickle Cell Disease Treatment Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025 |
| Sickle Cell Disease Treatment Market in Asia-Pacific by Drug Type: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Sickle Cell Disease Treatment Historic Market Scenario in US$ Thousand by Drug Type: 2009-2017 |
| Asia-Pacific Sickle Cell Disease Treatment Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025 |
| REST OF WORLD |
| Rest of World Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Disease Type: 2018 to 2025 |
| Rest of World Sickle Cell Disease Treatment Historic Market Review by Disease Type in US$ Thousand: 2009-2017 |
| Sickle Cell Disease Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025 |
| Rest of World Sickle Cell Disease Treatment Market Estimates and Forecasts in US$ Thousand by Drug Type: 2018 to 2025 |
| Rest of World Sickle Cell Disease Treatment Historic Market Review by Drug Type in US$ Thousand: 2009-2017 |
| Sickle Cell Disease Treatment Market in Rest of World: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 8 Click here to request a full table of contents and more details on this project. |
| V. CURATED RESEARCH |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com